Floatz logo

5-azacytidine

Recurrent Glioma

National Cancer Institute (NCI)Phase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

19 Active assets in the Recurrent Glioma cohort.

Asset / SponsorPhaseRating
Cediranib
National Cancer Institute (NCI)
Phase 2B
Talzenna
The University of Hong Kong
Phase 2B
PI3K/MTOR INHIBITOR LY3023414
National Cancer Institute (NCI)
Phase 2B
Olaparib
University Health Network, Toronto
Phase 2B
Palbociclib
National Cancer Institute (NCI)
Phase 2B

View all 21 →

Same molecule, other indications

5-azacytidine is also rated in:

Recurrent Non-Hodgkin LymphomaDormant
BB
Indicative ·
70 / 100
View asset →
Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic LeukemiaDormant
BB
Indicative ·
65 / 100
View asset →
myelodysplastic syndromeDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →